Sanofi Lost Actelion Bid to J&J After Price Turnabout

Source: Bloomberg

Feb 16, 2017

According to a Bloomberg report, Sanofi’s bid for Actelion last December wasn’t as high as it was initially thought to be.

While Actelion were in negotiations with Johnson & Johnson, Actelion received a higher-priced offer from Sanofi. Actelion and J&J ended discussion on Dececember 14 after J&J said it would not match the Sanofi offer.

When Actelion met with Sanofi on December 19, it had suddenly lowered its proposed asking price. The move caused the Actelion board to restart talks with J&J.

According to the Bloomberg report, while Sanofi sent letters to Actelion on December 21 and January 20 that said it was willing to buy the company according to the prospectus, the Actelion board ultimately finished the deal with J&J, releasing an announcement January 26.

Read the Bloomberg report

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments